The administrative core will provide the leadership to ensure that this center continually stimulates new, significant and innovative research while simultaneously providing new "cutting edge approaches" to enhance the goals of the research projects funded to investigators at this and neighboring institutions. The director of this center will have the responsibility for all aspects of this center but will be provided with daily input from the internal advisory committee some of whom have been colleagues for decades, and frequently from the external advisory committee. In addition the individual core leaders will serve in an advisory capacity with the major goal to stimulate new innovative research available due to collaboration among the cores. This core will rely heavily on continual interaction and communication among all scholars and advisors as they have done for years. There has been a long history of collaboration among the drug abuse researchers at this and neighboring institutions and this experience will provide the essence for the leadership of this center. Should it be necessary the internal advisory committee for this center along with the dean of the School of Medicine will designate one of the core directors or another senior investigator in the drug abuse field to become the center director. The administrative support for this center will be provided by the secretarial and financial personnel as requested in this application but they will have the very large and experienced administrative staff of the Department of Pharmacology and Toxicology as needed. Further, the offices of the School of Medicine and The Vice President for Research have and will continue to provide support at their respective levels.
The administrative core of this center will maintain the responsibility to ensure that the research carried out will be of such that it will lead to improvement in prevention and treatment of substance abuse diseases. The cores of this center have been chosen in part due to their applicability for translational research which is the central element of new treatments for these diseases.
|Wiley, Jenny L; Walentiny, D Matthew; Wright Jr, M Jerry et al. (2014) Endocannabinoid contribution to ?9-tetrahydrocannabinol discrimination in rodents. Eur J Pharmacol 737:97-105|
|Schlosburg, Joel E; Kinsey, Steven G; Ignatowska-Jankowska, Bogna et al. (2014) Prolonged monoacylglycerol lipase blockade causes equivalent cannabinoid receptor type 1 receptor-mediated adaptations in fatty acid amide hydrolase wild-type and knockout mice. J Pharmacol Exp Ther 350:196-204|
|Samano, Kimberly L; Poklis, Justin L; Lichtman, Aron H et al. (2014) Development of a high-performance liquid chromatography-tandem mass spectrometry method for the identification and quantification of CP-47,497, CP-47,497-C8 and JWH-250 in mouse brain. J Anal Toxicol 38:307-14|
|Suzuki, Joji; Poklis, Justin L; Poklis, Alphonse (2014) "My friend said it was good LSD": a suicide attempt following analytically confirmed 25I-NBOMe ingestion. J Psychoactive Drugs 46:379-82|
|Poklis, Justin L; Clay, Deborah J; Poklis, Alphonse (2014) High-performance liquid chromatography with tandem mass spectrometry for the determination of nine hallucinogenic 25-NBOMe designer drugs in urine specimens. J Anal Toxicol 38:113-21|
|Lazenka, Matthew F; David, Bethany G; Lichtman, Aron H et al. (2014) Delta FosB and AP-1-mediated transcription modulate cannabinoid CB? receptor signaling and desensitization in striatal and limbic brain regions. Biochem Pharmacol 91:380-9|
|Sexton, Michelle; Cudaback, Eiron; Abdullah, Rehab A et al. (2014) Cannabis use by individuals with multiple sclerosis: effects on specific immune parameters. Inflammopharmacology 22:295-303|